

Filed on behalf of Petitioner COALITION FOR AFFORDABLE DRUGS IV LLC

By: Jeffrey S. Ward (Reg. No. 32,774)  
MERCHANT & GOULD, P.C.  
10 E. Doty Street  
Suite 600  
Madison, WI 53703-3376  
Telephone: (608) 280-6751  
FAX: (612) 332-9081

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

COALITION FOR AFFORDABLE DRUGS IV LLC  
Petitioner

v.

PHARMACYCLICS, INC.  
Patent Owner

---

Case No. To Be Assigned  
Patent No. 8,754,090

---

**DECLARATION BY DJORDJE ATANACKOVIC, M.D.,  
REGARDING U.S. PATENT NO. 8,754,090  
UNDER 37 C.F.R. § 42.63(a)**

---

I, Djordje Atanackovic, M.D., declare and state as follows:

**I. Background and Experience**

1. I graduated from Free University of Berlin in Germany in 2000 with a Doctorate of Medicine (M.D.) and completed my internal medicine residency in 2000 from the University Medical Center Hamburg-Eppendorf in Germany.

2. I completed my postdoctoral training in tumor immunology in 2003 from the Ludwig Institute for Cancer Research in New York.

3. I am board certified in internal medicine, hematology and oncology.

4. Between 2000 and 2014, I have held various research, development, and clinical position of increasing responsibility including positions at the University of Utah Huntsman Cancer Institute, the University Medical Center Hamburg-Eppendorf, and the Ludwig Institute for Cancer Research.

5. At the University of Utah Huntsman Cancer Institute, I am the Director of the Multiple Myeloma Program and of Cancer Immunotherapy. In my role as Director, I manage several research projects including acting as the principal investigator of numerous clinical studies involving new drugs for the treatment of various cancers, including hematologic cancers.

6. I also treat patients with a variety of hematologic malignancies with a focus on Multiple Myeloma and B-cell lymphomas. Therapeutic regimens I use comprise of different types of chemotherapies including high-dose chemotherapy plus autotransplant, tyrosine kinase inhibitors, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies.

7. My research focuses on immunotherapeutic approaches for patients with hematologic malignancies, including multiple myeloma and B-cell non-Hodgkin's lymphomas, such as mantle cell lymphoma. My research has developed numerous cellular and antibody based approaches for patients with blood cancer and as a result, many of those immunotherapeutic approaches have been introduced into the clinic as part of a treatment protocol.

8. I am the principal investigator in multiple clinical trials in different human malignancies. One clinical study was a Phase 1/2 dose escalation safety, pharmacokinetic, and efficacy study of multiple intravenous administrations of a humanized monoclonal antibody (SAR640984) against CD38 in patients with selected CD38+ hematologic malignancies including different B-cell lymphomas.

9. I regularly publish peer-reviewed articles with my colleagues in medicine and science. I am the author of at least eighty (80) peer-reviewed publications.

10. My most recent publication relates to the expression of certain proteins in cancers cells of patients with multiple myeloma, a blood cancer. It was published in the Blood Cancer Journal in 2015.

11. I am an active member of the medical and research community. I am an editor for *BMC Cancer*, a peer-reviewed medical journal that publishes original research on cancer. I am also a grant reviewer for several organizations including the European Commission, Leukemia & Lymphomas Research U.K., Cancer Research UK, FWF in Austria, the German Cancer Aid, the Research Foundation Flanders in Belgium, the Catalan Agency for Health Information in Spain, and the Italian Ministry of Health.

12. I am a current member of the American Society of Hematology (ASH), the European Hematology Association (EHA), the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the European Association for Cancer Research (EACR).

13. I am also the named inventor on several patents and patent applications, including an issued patent directed to the diagnosis and therapy of hematological malignancies.

14. I have won numerous awards for my research including the Science Award of the Hamburg Cancer Society, the Clinical Science Award of the German Society for Immune and Targeted Therapy, and the investigator award of the Cancer Research Institute (CRI).

15. A copy of my CV is attached to this report as Exhibit 1022.

16. I am not employed by, nor am I receiving grant support from the Petitioner or any of the other parties in interest. I am receiving compensation for my involvement in this matter based on my standard hourly consulting rate.

17. I am competent to make this declaration based upon my personal knowledge and expertise in the area of treatment of and research into hematologic cancers, including B-cell non-Hodgkin's lymphomas.

## **II. Legal Principles Used In Analysis**

18. I have been asked to provide my opinion on whether the claims of the '090 patent would have been anticipated or obvious to a person of ordinary skill in the art ("POSA") at the time of the '090 patent.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.